”This investment is expected to create tens of thousands of new, highly qualified direct and indirect jobs across the country, drive growth and deliver next-generation medicines to patients in the US and around the world”, the company writes in a press release.
The cornerstone of the investment, which corresponds to approximately 480 billion kronor, is the construction of a new factory for the production of pharmaceutical substances in the state of Virginia. The factory is described by Astra Zeneca as the company's single largest manufacturing investment in the world.
The company is also investing in a number of new and existing projects in states such as Maryland, Massachusetts, California, and Texas.
Overall, Astra Zeneca now hopes to achieve its goal of total sales of $80 billion by 2030, with the expectation that "50 percent will be generated in the US”.
US President Donald Trump has, within the framework of his tariff policy, urged companies, not least pharmaceutical companies, to move production to American soil.
Astra Zeneca currently has 19 facilities and offices in the US with over 18,000 employees.
